Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Organovo (NASDAQ:ONVO) in a research report issued to clients and investors on Friday. The brokerage set a “sell” rating on the medical research company’s stock.

Organovo Trading Down 2.3 %

NASDAQ ONVO opened at $2.12 on Friday. Organovo has a 12-month low of $1.96 and a 12-month high of $21.96. The company has a fifty day simple moving average of $4.70 and a two-hundred day simple moving average of $4.95. The stock has a market cap of $3.61 million, a P/E ratio of -2.49 and a beta of 1.13.

Organovo (NASDAQ:ONVO) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) EPS for the quarter, topping analysts’ consensus estimates of ($2.52) by $0.24. Organovo had a negative return on equity of 346.26% and a negative net margin of 10,151.64%. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.05 million. As a group, sell-side analysts forecast that Organovo will post -0.77 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.